Ascendis Pharma’s Yorvipath (palopegteriparatide) has received FDA approval for the treatment of hypoparathyroidism in adults. This approval fills a crucial gap in treatment options for this rare condition, particularly as Takeda’s Natpar/Natpara will be discontinued in 2024. Yorvipath is expected to be available in the first quarter of 2025.